Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

Multiple Myeloma (MM)

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Blood Cancer J

Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ

doi: 10.1038/s41408-026-01469-z

Multiple Myeloma (MM)

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Clin Cancer Res

Suvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K

doi: 10.1158/1078-0432.CCR-25-4068

Multiple Myeloma (MM)

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data

Br J Haematol

Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D

doi: 10.1111/bjh.70490

Multiple Myeloma (MM)

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Br J Haematol

Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault MJ, Raje N, Duffy C, Costello P, Cruz JD, Looka A, Nohria A

doi: 10.1111/bjh.70216

Multiple Myeloma (MM)

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Bone Marrow Transplant

Rasche L, Krauth MT, Agis H, Renner C, Strassl I, Teipel R, Vučinić V, Weisel K, Willenbacher W, Raab MS

doi: 10.1038/s41409-026-02905-1

Multiple Myeloma (MM)

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Ann Hematol

Benda M, Reimann P, Willenbacher W, Gunsilius E, Weisel K, Strassl I, Krauth MT, Knop S, Winder T, Steiner N

doi: 10.1007/s00277-026-07140-8

Multiple Myeloma (MM)

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Leuk Lymphoma

Leitner T, Oelschläger L, Henriquez Mosquera F, Schaefers C, Leypoldt L, Weisel K, von Bubnoff N, Rückert M, Kimmich C, Ahmed H, Vorwerk J, Khandanpour C

doi: 10.1080/10428194.2026.2699285

Multiple Myeloma (MM)

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Leuk Lymphoma

Park H, Robinson J, Flanagan C, Pawlyn C, Jackson G, Jones JR

doi: 10.1080/10428194.2025.2560085

Lymphoma

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol

Br J Haematol

Mikhaeel NG, Bouziana S, Northend M, Brady JL, Sanderson R, Sivabalasingham S, Springell D, Roddie C, Bourlon C, Farias MC, Davila AM, Benjamin R, Patten PEM, Kumar E, Yallop D, Hwang A, Kamat S, Ntentas G, Kuhnl A

doi: 10.1111/bjh.70653

Related content

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol